🇺🇸 Remifentanil [Ultiva] in United States

5 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Blindness Cortical — 1 report (20%)
  2. Colour Blindness Acquired — 1 report (20%)
  3. Hallucination, Visual — 1 report (20%)
  4. Hemianopia Homonymous — 1 report (20%)
  5. Neurotoxicity — 1 report (20%)

Source database →

Remifentanil [Ultiva] in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Remifentanil [Ultiva] approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Remifentanil [Ultiva] in United States?

Medical University of Warsaw is the originator. The local marketing authorisation holder may differ — check the official source linked above.